Welcome to our dedicated page for KEWAUNEE SCIENTIFIC /DE/ SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KEWAUNEE SCIENTIFIC /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KEWAUNEE SCIENTIFIC /DE/'s regulatory disclosures and financial reporting.
Kewaunee Scientific senior vice president of manufacturing operations Douglas J. Batdorff reported a set of compensation-related equity transactions. On June 30, 2026, he acquired 7,451 shares of common stock through the settlement of restricted stock units, while 851 shares were withheld to cover tax obligations and 5,609 shares were disposed of back to the company for cash instead of receiving shares. Footnotes note that 3,739 performance-based RSUs vested at 150% of target and 535 service-based RSUs vested the same day.
Kewaunee Scientific Chief Financial Officer Donald T. Gardner III reported a series of equity compensation events on June 30, 2026. He exercised and settled various restricted stock units into common stock, including performance-based RSUs that vested at 150% of target. As part of the settlement, 4,027 shares of common stock at $36.25 per share were withheld to cover tax obligations, and 12,000 shares were delivered to the company pursuant to his prior election for cash settlement. Footnotes state that, in total, 11,397 performance-based RSUs were settled and 6,723 shares were received from RSU settlements, along with a cash payment in lieu of additional shares.
Kewaunee Scientific President and CEO Thomas David Hull III reported several compensation-related share transactions tied to restricted stock units. On June 30, 2026, he exercised or settled awards to acquire common stock and used part of the shares to cover obligations.
Hull exercised or settled awards covering 54,388 shares of common stock. Of these, 16,243 shares were delivered at $36.25 per share to satisfy tax obligations, and 17,000 shares were disposed to the issuer for cash under his election. Footnotes state that service- and performance-based RSUs convert one-for-one into common stock.
Footnotes also explain that 28,929 performance-based RSUs were settled at 150% of target, resulting in 26,393 shares plus cash in lieu of 17,000 shares, and 4,132 service-based RSUs vested. Overall, the filing reflects routine equity compensation vesting, tax withholding, and related dispositions rather than open-market trading.
Kewaunee Scientific Corporation ownership disclosure: Minerva Advisors LLC, Minerva Group LP, Minerva GP, LP, Minerva GP, Inc., and David P. Cohen report beneficial ownership stakes in the issuer's common stock.
The filing states specific holdings: Minerva Advisors LLC and David P. Cohen are each shown as beneficial owners of 149,410 shares (5.2%), while Minerva Group LP, Minerva GP, LP and Minerva GP, Inc. each hold 103,167 shares (3.6%). The filing cites 2,870,410 shares outstanding as of 6/24/2026 from the issuer's Form 10-K.
Kewaunee Scientific Corporation reports fiscal 2026 results showing net sales of $281.999 million, up from $240.472 million, driven largely by the November 2024 acquisition of Nu Aire. Lab Products Group sales reached $214.9 million and International segment sales were $67.1 million.
Gross margin was 28.5% of sales, essentially flat year over year, while operating expenses rose to $63.7 million, reflecting Nu Aire integration and higher corporate costs, including Sarbanes-Oxley 404(b) readiness. Net earnings attributable to Kewaunee declined to $9.618 million, or $3.22 per diluted share, from $11.405 million, or $3.83 per diluted share.
Order backlog decreased to $165.9 million at April 30, 2026 from $214.6 million, with Lab Products Group backlog at $118.8 million and International at $47.1 million. Cash from operations was $18.6 million, term loans totaled $20.1 million, and management believes current liquidity and its $20 million revolving credit facility support capital needs through fiscal 2027.
Phillips Elizabeth D reported acquisition or exercise transactions in this Form 4 filing.
KEWAUNEE SCIENTIFIC CORP senior vice president of People & Culture, Elizabeth D. Phillips, received a compensation grant of 2,466 restricted stock units tied to the company’s common stock. Each unit represents a contingent right to one share and will vest in three equal annual installments beginning on June 30, 2027, subject to her continued employment. Following this award, her reported holdings from this grant total 2,466 units.
Ranade Mandar reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific senior vice president of IT & Engineering Mandar Ranade received a grant of 2,635 restricted stock units tied to the company’s common stock. Each unit represents a right to one share. The award will vest in three equal annual installments beginning on June 30, 2027, contingent on continued employment.
Noble Ryan S. reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific reported that senior vice president of Sales & Marketing Development Ryan S. Noble received a grant of 2,628 Restricted Stock Units (RSUs) for FY27 on June 24, 2026. Each RSU represents a contingent right to receive one share of common stock. The RSUs vest in three equal annual installments beginning June 30, 2027, subject to his continued employment with the company. Following this compensation-related award, Noble holds 2,628 RSUs linked to Kewaunee Scientific common stock.
Batdorff Douglas J. reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific senior vice president of manufacturing operations Douglas J. Batdorff received a grant of 2,717 restricted stock units tied to the company’s common stock. Each unit represents a right to one share. Following this grant, he holds 2,717 restricted stock units directly.
The award will vest in three equal annual installments beginning on June 30, 2027, and is contingent on his continued employment with the company. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Gardner Donald T. III reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific reported that Chief Financial Officer Donald T. Gardner III received a compensation-related grant of derivative securities. He was awarded 5,428 restricted stock units linked to the company’s common stock, with each unit representing the right to receive one share in the future.
The restricted stock units will vest in three equal annual installments beginning on June 30, 2027, conditioned on his continued employment with the company. Following this grant, his reported holding of these FY27 restricted stock units is 5,428 units.